Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated With Immune‐Checkpoint Inhibitors
Oncologist - United States
doi 10.1634/theoncologist.2018-0563
Full Text
Open PDFAbstract
Available in full text
Date
April 23, 2019
Authors
Publisher
Alphamed Press